A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines

Yingji Jin, Hyoung Jin Kim, Ga Won Yim, YoungTae Kim, Don Yong Chang, Hong Jin Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Two types of prophylactic human papillomavirus (HPV) vaccines are currently available. However, there is no simple monitoring system for assessing acquired immunity that can cope simultaneously with large numbers of serum samples. Approximately 30% of women with normal cytology are known to be seropositive for HPV types 16 and 18 because of the high prevalence of these HPV types. Therefore, to be useful the monitoring system has to discriminate clearly between vaccine recipients and other serology groups. However, there has never been any focus on developing a method to satisfy this condition. In this study, we developed a high-throughput single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-HPV antibody titres following vaccination. We optimised the conditions for each ELISA step to increase its accuracy and precision and to avoid the high background of non-specific reactions that is a major problem for serology assays. The new ELISA system has superior linearity, accuracy and reproducibility. Moreover, it clearly discriminated between antibody levels in vaccine recipients and those in other serology groups such as individuals with normal cervical cytology and those with cervical cancer. Therefore, this single-serum-dilution ELISA should be very useful for assessing the acquired immunity of HPV vaccine recipients.

Original languageEnglish
Pages (from-to)352-355
Number of pages4
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume66
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Papillomavirus Vaccines
Immunosorbents
Immunoenzyme Techniques
Dilution
Assays
Serology
Enzyme-Linked Immunosorbent Assay
Cytology
Antibodies
Adaptive Immunity
Enzymes
Serum
Cell Biology
Vaccines
Human papillomavirus 18
Human papillomavirus 16
Monitoring
Uterine Cervical Neoplasms
Vaccination
Throughput

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

@article{2495cfcbed534c3f85403b9662613a3f,
title = "A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines",
abstract = "Two types of prophylactic human papillomavirus (HPV) vaccines are currently available. However, there is no simple monitoring system for assessing acquired immunity that can cope simultaneously with large numbers of serum samples. Approximately 30{\%} of women with normal cytology are known to be seropositive for HPV types 16 and 18 because of the high prevalence of these HPV types. Therefore, to be useful the monitoring system has to discriminate clearly between vaccine recipients and other serology groups. However, there has never been any focus on developing a method to satisfy this condition. In this study, we developed a high-throughput single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-HPV antibody titres following vaccination. We optimised the conditions for each ELISA step to increase its accuracy and precision and to avoid the high background of non-specific reactions that is a major problem for serology assays. The new ELISA system has superior linearity, accuracy and reproducibility. Moreover, it clearly discriminated between antibody levels in vaccine recipients and those in other serology groups such as individuals with normal cervical cytology and those with cervical cancer. Therefore, this single-serum-dilution ELISA should be very useful for assessing the acquired immunity of HPV vaccine recipients.",
author = "Yingji Jin and Kim, {Hyoung Jin} and Yim, {Ga Won} and YoungTae Kim and Chang, {Don Yong} and Kim, {Hong Jin}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.jpba.2012.03.011",
language = "English",
volume = "66",
pages = "352--355",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines. / Jin, Yingji; Kim, Hyoung Jin; Yim, Ga Won; Kim, YoungTae; Chang, Don Yong; Kim, Hong Jin.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 66, 01.07.2012, p. 352-355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines

AU - Jin, Yingji

AU - Kim, Hyoung Jin

AU - Yim, Ga Won

AU - Kim, YoungTae

AU - Chang, Don Yong

AU - Kim, Hong Jin

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Two types of prophylactic human papillomavirus (HPV) vaccines are currently available. However, there is no simple monitoring system for assessing acquired immunity that can cope simultaneously with large numbers of serum samples. Approximately 30% of women with normal cytology are known to be seropositive for HPV types 16 and 18 because of the high prevalence of these HPV types. Therefore, to be useful the monitoring system has to discriminate clearly between vaccine recipients and other serology groups. However, there has never been any focus on developing a method to satisfy this condition. In this study, we developed a high-throughput single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-HPV antibody titres following vaccination. We optimised the conditions for each ELISA step to increase its accuracy and precision and to avoid the high background of non-specific reactions that is a major problem for serology assays. The new ELISA system has superior linearity, accuracy and reproducibility. Moreover, it clearly discriminated between antibody levels in vaccine recipients and those in other serology groups such as individuals with normal cervical cytology and those with cervical cancer. Therefore, this single-serum-dilution ELISA should be very useful for assessing the acquired immunity of HPV vaccine recipients.

AB - Two types of prophylactic human papillomavirus (HPV) vaccines are currently available. However, there is no simple monitoring system for assessing acquired immunity that can cope simultaneously with large numbers of serum samples. Approximately 30% of women with normal cytology are known to be seropositive for HPV types 16 and 18 because of the high prevalence of these HPV types. Therefore, to be useful the monitoring system has to discriminate clearly between vaccine recipients and other serology groups. However, there has never been any focus on developing a method to satisfy this condition. In this study, we developed a high-throughput single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-HPV antibody titres following vaccination. We optimised the conditions for each ELISA step to increase its accuracy and precision and to avoid the high background of non-specific reactions that is a major problem for serology assays. The new ELISA system has superior linearity, accuracy and reproducibility. Moreover, it clearly discriminated between antibody levels in vaccine recipients and those in other serology groups such as individuals with normal cervical cytology and those with cervical cancer. Therefore, this single-serum-dilution ELISA should be very useful for assessing the acquired immunity of HPV vaccine recipients.

UR - http://www.scopus.com/inward/record.url?scp=84861222164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861222164&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2012.03.011

DO - 10.1016/j.jpba.2012.03.011

M3 - Article

VL - 66

SP - 352

EP - 355

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -